TTrialPathMatch Me to Trials
← Back to trials
RecruitingPrimary Progressive Aphasia

Communication Bridge 3 Study

Eligible age

18–100 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The aim of the study is to help us better understand the effects of speech-language therapy on communication abilities in individuals with PPA.

Sponsor: University of Chicago

You may qualify if…

  • 1. Meets diagnostic criteria for PPA based on neurologist and supporting medical assessments (extracted from medical records)
  • 2. English as primary language used in daily communication activities (by self-report)
  • 3. Adequate hearing (aided or unaided) for communicating with others in a crowded room (by self-report)
  • 4. Adequate vision (aided or unaided) for reading a newspaper, or other functional materials (by self-report)
  • 5. Able to pass technology screening and demonstrates sufficient knowledge for use of video conference and Communication Bridge™ web application use (with or without training)
  • 6. Geriatric Depression Scale score ≤ 9
  • 7. Mild-moderate PPA informed by a structured interview with a speech-language pathologist and a standardized testing battery.
  • 1. 18+ years of age

You may not qualify if…

  • A dementia diagnosis other than Primary Progressive Aphasia
  • Participation is co-enrolled in an outside speech language therapy program during the study course.
  • Communication partners will be excluded if they have a pre-existing communication impairment that would affect study participation (e.g., aphasia, dementia)
  • Medical records will be requested and reviewed to determine eligibility

Where it's recruiting

Illinois

Chicago

Source: ClinicalTrials.gov · NCT06191198 · last updated 2026-06-01